Agenus Inc. is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer and infectious diseases. Headquartered in Massachusetts, the company focuses on activating the body's immune system through a portfolio of checkpoint inhibitors, immune modulators, and cell therapies. Agenus is notable for its proprietary Retrocyte Display antibody expression platform and its development of the QS-21 Stimulon vaccine adjuvant.
Agenus's revenue is highly concentrated in a single collaboration partner: 95%, 98% and 73% of revenue was earned from one collaboration partner for the years ended December 31, 2025, 2024 and 2023, respectively.